BIVIGAM® will no longer be available for sale or distribution in 2017
Distribution agreement between Biotest and Kedrion Biopharma has been terminated
KEDPLASMA Advances Long-Range Growth Plan
KEDPLASMA acquires 2 FDA-licensed and EU-certified plasma collection centers from IMMUNOTEK
Kedrion Biopharma attends ASHP 2016 midyear clinical meeting
Kedrion Biopharma has recognized the changing role of pharmacists in the decision-making process
Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment
FDA has accepted for review a BLA for a human anti-rabies immunoglobulin (IgG) therapy
Kedrion Biopharma set for strong presence at 2016 IgNS Meeting
Kedrion Biopharma will be a bronze sponsor at the Immunoglobulin National Society (IgNS) 2016 5th National Conference
Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin
Kamada and Kedrion, collaborators on development and commercialization of post-exposure treatment for suspected rabies, announced today the filing of a BLA with the FDA.
Kedrion Biopharma to attend 14th International Symposium of GBS/CIPD Foundation
Kedrion Biopharma will be a Silver Sponsor at the 14th International Symposium of GBS/CIPD Foundation
KEDPLASMA USA opens 13th center in the United States
KEDPLASMA USA, a Kedrion Biopharma company, has announced the opening of a new plasma collection center in Gastonia, NC.
Kedrion Biopharma extends its focus on patients by offering Mix2Vial
A needle-free, double-ended, all plastic filter transfer set for use in reconstituting Koate®-DVI
CURhE, Global Alliance for mother and child healthcare
Kedrion among the founding members with a goal of Rh disease eradication